Skip to main content
L&C BIO Co., Ltd logo

L&C BIO Co., Ltd — Investor Relations & Filings

Ticker · 290650 ISIN · KR7290650001 KO Manufacturing
Open in API
Filings indexed 378 across all filing types
Latest filing 2024-12-13 Regulatory Filings
Country KR South Korea
Listing KO 290650

About L&C BIO Co., Ltd

http://www.lncbio.co.kr/?locale=en_US

L&C BIO Co., Ltd. is a biotechnology company specializing in regenerative medicine. The company develops, manufactures, and commercializes human tissue-based medical devices and allograft treatment materials. Its core operations include the processing, storage, and distribution of human tissues, with a focus on skin, musculoskeletal, and soft tissues, utilizing patented processing technologies. The company's product portfolio also extends to other medical devices and cosmetics. L&C BIO supports its activities through dedicated research and development centers and manufacturing facilities, including a human tissue plant and a pharmaceutical plant, to advance its pipeline and serve global markets.

Recent filings

Filing Released Lang Actions
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory notice regarding the setting of a record date and shareholder register closure for an upcoming Annual General Meeting (AGM). It does not contain the full AGM materials or proxy statements, but rather serves as a formal regulatory announcement of the meeting's administrative preparation. Given it is a standard regulatory notification that does not fit into specific categories like 'AGM-R' (which implies presentation materials) or 'PSI' (which implies proxy solicitation materials), it is best classified as a general regulatory filing.
2024-12-13 Korean
현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement from L&C Bio regarding a decision to pay cash dividends. It specifies the dividend amount per share, the total dividend amount, the record date, and the board approval date. This fits the definition of a 'Notice of Dividend Amount' (DIV) as it provides specific details regarding dividend payments to shareholders.
2024-12-13 Korean
분기보고서 (2024.09)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for the company '주식회사 엘앤씨바이오' covering the period from January 1, 2024, to September 30, 2024. It contains detailed financial statements, business descriptions, and management analysis, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2024
2024-11-14 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status, changes in shareholding, and contractual relationships (such as collateral agreements) of a major shareholder (Lee Whan-chul) and his special related parties in the company 'L&C Bio'. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema, as it tracks significant ownership levels and changes therein.
2024-11-01 Korean
전환가액의조정
Capital/Financing Update Classification · 100% confidence The document is an official regulatory filing regarding the adjustment of the conversion price of convertible bonds (CB) due to a decline in the market price of the company's stock. This type of disclosure is a standard capital structure update related to financing instruments. Since it specifically details the change in conversion price and the resulting change in the number of convertible shares, it falls under the 'Capital/Financing Update' category.
2024-09-30 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed by L&C Bio. This is a standard regulatory filing in South Korea (DART system) used to disclose insider transactions and changes in share ownership by directors and major shareholders. This corresponds to the 'Director's Dealing' category, which covers reports of personal share transactions by company directors and executives.
2024-09-30 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.